AU5135396A - Biosynthetic virus vectors for gene therapy - Google Patents

Biosynthetic virus vectors for gene therapy

Info

Publication number
AU5135396A
AU5135396A AU51353/96A AU5135396A AU5135396A AU 5135396 A AU5135396 A AU 5135396A AU 51353/96 A AU51353/96 A AU 51353/96A AU 5135396 A AU5135396 A AU 5135396A AU 5135396 A AU5135396 A AU 5135396A
Authority
AU
Australia
Prior art keywords
biosynthetic
gene therapy
virus vectors
virus
vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU51353/96A
Inventor
Clague P Hodgson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nature Technology Corp
Original Assignee
Creighton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creighton University filed Critical Creighton University
Publication of AU5135396A publication Critical patent/AU5135396A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU51353/96A 1995-02-28 1996-02-28 Biosynthetic virus vectors for gene therapy Abandoned AU5135396A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39535595A 1995-02-28 1995-02-28
US395355 1995-02-28
PCT/US1996/002877 WO1996026745A1 (en) 1995-02-28 1996-02-28 Biosynthetic virus vectors for gene therapy

Publications (1)

Publication Number Publication Date
AU5135396A true AU5135396A (en) 1996-09-18

Family

ID=23562692

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51353/96A Abandoned AU5135396A (en) 1995-02-28 1996-02-28 Biosynthetic virus vectors for gene therapy

Country Status (3)

Country Link
EP (1) EP0824362A1 (en)
AU (1) AU5135396A (en)
WO (1) WO1996026745A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056353A1 (en) * 1997-06-13 1998-12-17 Navid Malik Internally supported lipid vesicle systems
WO1999006576A1 (en) 1997-08-04 1999-02-11 Calydon, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
IL105914A0 (en) * 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
EP0652775B1 (en) * 1992-07-27 2000-04-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Targeting of liposomes to the blood-brain barrier
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5470955A (en) * 1993-02-02 1995-11-28 Dartmouth College Antibodies which specifically bind mcl-1 polypeptide

Also Published As

Publication number Publication date
EP0824362A1 (en) 1998-02-25
WO1996026745A1 (en) 1996-09-06

Similar Documents

Publication Publication Date Title
AU2552795A (en) Safe vectors for gene therapy
AU699706C (en) Improved vectors for gene therapy
AU5153296A (en) Vectors for gene delivery
AU5638496A (en) Viral vectors
AU5723696A (en) Gene therapy using replication competent targeted adenoviral vectors
AU5671696A (en) Scytalidium catalase gene
AU6011496A (en) Improved pharmaceutical compositions for gene therapy
AU4787697A (en) Therapeutic gene
AU5586398A (en) Submersive therapy apparatus
AU7019494A (en) Genetic therapy for cardiovascular disease
AU5268696A (en) Novel compounds and methods for therapy
AU5316096A (en) Gene therapy by secretory gland expression
AU690034B2 (en) Sequence controller
AU6535096A (en) Methods and means for targeted gene delivery
AU3737297A (en) Bacteriophage-mediated gene therapy
AU3169495A (en) Gene therapy for restenosis using an adenoviral vector
AU6489996A (en) Methods for increasing protein expression
AU2721997A (en) Design of novel highly efficient hiv based packaging systems for gene therapy
IL117713A0 (en) Gene expression system
AU5315796A (en) Mammalian expression vectors
AU4401297A (en) Improved retroviral vectors for gene therapy
AU4425397A (en) Antisense gene therapy for rna viruses
AU6254799A (en) Anti-ige gene therapy
AU4941096A (en) Self-deleting vectors for gene therapy
AU5135396A (en) Biosynthetic virus vectors for gene therapy